TNF alpha antagonist therapy and safety monitoring

详细信息    查看全文

• 作者：Thao Pham¹ ; ^{thao.pham@mail.ap-hm.fr"" rel=""nofollow} ; Herv&#xe9 ; Bachelez² ; Jean-Marie Berthelot³ ; Jacques Blacher⁴ ; Yoram Bouhnik⁵ ; Pascal Claudepierre⁶ ; Arnaud Constantin⁷ ; Bruno Fautrel⁸ ; Philippe Gaudin⁹ ; Vincent Goë ; b¹⁰ ; Laure Gossec¹¹ ; Philippe Goupille¹² ; S&#xe9 ; verine Guillaume-Czitrom¹³ ; Eric Hachulla¹⁴ ; Isabelle Huet¹⁵ ; Denis Jullien¹⁶ ; Odile Launay¹⁷ ; Marc Lemann¹⁸ ; Jean-Francis Maillefert¹⁹ ; Jean-Pierre Marolleau²⁰ ; Val&#xe9 ; rie Martinez²¹ ; Charles Masson²² ; Jacques Morel²³ ; Luc Mouthon²⁴ ; Stanislas Pol²⁵ ; Xavier Pu&#xe9 ; chal²⁶ ; Pascal Richette²⁷ ; Alain Saraux²⁸ ; Thierry Schaeverbeke²⁹ ; Martin Soubrier³⁰ ; Anne Sudre⁹ ; Tu-Anh Tran¹³ ; Manuelle Viguier² ; Olivier Vittecoq¹⁰ ; Daniel Wendling³¹ ; Xavier Mariette³² ; Jean Sibilia³³
• 刊名：Joint Bone Spine
• 出版年：2011
• 出版时间：May 2011
• 年：2011
• 卷：78
• 期：Complete
• 页码：15-185
• 全文大小：6301 K

文摘

Objectives

To develop and/or update fact sheets about TNFα antagonists treatments, in order to assist physicians in the management of patients with inflammatory joint disease.

Methods

1. selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable;

2. identification and review of publications relevant to each topic;

3. development and/or update of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of chronic inflammatory diseases, such as rheumatoid. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Société Francaise de Rhumatologie. Each fact sheet was revised by several experts and the overall process was coordinated by three experts.

Results

Several topics of major interest were selected: contraindications of TNFα antagonists treatments, the management of adverse effects and concomitant diseases that may develop during these therapies, and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points:

1. in RA and SpA, initiation and monitoring of TNFα antagonists treatments, management of patients with specific past histories, and specific clinical situations such as pregnancy;

2. diseases other than RA, such as juvenile idiopathic arthritis;

3. models of letters for informing the rheumatologist and general practitioner;

4. and patient information.

Conclusion

These TNFα antagonists treatments fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on these therapies. They will be available continuously at www.cri-net.com and updated at appropriate intervals.